Skip to main navigation Skip to search Skip to main content

Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Chronic hepatitis B and C infection are the leading causes of hepatocellular carcinoma and liver related death in the world and in the United States respectively. Screening guidelines have been developed based on estimated prevalence determined by NHANES data. However, individuals with the most risk of chronic infection (incarcerated, homeless, immigrants, nursing home residents, and hospitalized persons) are underrepresented in this cohort leading to an underestimation of the true prevalence of chronic hepatitis B and C infection. This has led to recent updates in the screening guidelines. This review examines the change in the guidelines, the likely true seroprevalence of hepatitis B and C virus, as well as the burden of chronic infection in this population.

Original languageEnglish
Pages (from-to)511-521
Number of pages11
JournalExpert Review of Anti-Infective Therapy
Volume14
Issue number5
DOIs
StatePublished - 3 May 2016

Keywords

  • Chronic hepatitis B
  • chronic hepatitis C
  • guidelines
  • prevalence
  • screening

Fingerprint

Dive into the research topics of 'Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening'. Together they form a unique fingerprint.

Cite this